NCT02963688View on ClinicalTrials.gov

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

298

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
Interventions
GENETIC

Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform

BRCA1,2 Germline /Somatic mutation test

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER